No difference in CDC activation via glycoengineered FcαRI BsAbs. (A + B) CDC of (A) A431 and (B) MC38cEGFR by glycoengineered BsAbs 0.1 or 1.0 µg/ml. Data is presented as mean ± standard deviations (SD); n = 3 per group (*P < 0.05). Two-way ANOVA with Tukey’s multiple-comparison correction was performed. Representative experiments out of 3 independent experiments are shown.